VistaGen Therapeutics (VTGN) Q4 2024 earnings summary

Executive summary

• Achieved positive Phase III results for fasedienol in social anxiety disorder (SAD), marking the first positive Phase III for acute SAD treatment, and initiated PALISADE-3 with PALISADE-4 planned for 2H 2024.

• Advanced a diversified pipeline, including successful Phase I for itruvone in MDD and positive Phase IIA data for PH80 in menopausal hot flashes and PMDD.

• Strengthened leadership with a new CFO and secured a public offering to support ongoing clinical programs.

• Received industry recognition for workplace mental health and well-being, including the Platinum Bell Seal Award and Great Place to Work certification.

Financial highlights

• Research and development expenses were $20 million for FY2024, down from $44.4 million in the prior year.

• General and administrative expenses were $14.1 million, compared to $14.7 million the previous year.

• Net loss attributable to common stockholders was $29.4 million, compared to $59.2 million in the prior year.

• Cash and cash equivalents totaled $119.2 million as of March 31, 2024.

• Revenue was $1.1 million for FY2024, compared to a loss of $0.2 million in FY2023.

Outlook and guidance

• PALISADE-3 trial is on track for top-line data by mid-2025; PALISADE-4 expected to complete by end of 2025.

• A placebo-controlled repeat dose study for fasedienol will be initiated in 2H 2024, with results anticipated by late 2025.

• Potential U.S. new drug application for fasedienol in SAD targeted for the first half of 2026.

• Preparations ongoing for U.S. Phase IIB development of itruvone for MDD and further Phase II development for PH80 in menopausal hot flashes.

• Cash runway expected to support execution of critical milestones in registration-directed programs.